News
2don MSN
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...
4d
Everyday Health on MSNZepbound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.
2don MSN
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.
True or False: Pooled trial data showed that rheumatoid arthritis patients taking tofacitinib (Xeljanz) were less likely to ...
3h
WANE 15 on MSNAre weight loss drugs safe? Learn some of the side effectsWeight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past ...
Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.
Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...
By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results